 Kevin Lillehei
Concepts (605)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 48 | 2023 | 1022 | 3.700 |
Why?
| | Pituitary Neoplasms | 26 | 2020 | 165 | 3.030 |
Why?
| | Adenoma | 21 | 2020 | 191 | 2.580 |
Why?
| | Meningioma | 12 | 2022 | 82 | 2.230 |
Why?
| | Pituitary Gland | 11 | 2020 | 163 | 1.940 |
Why?
| | Glioblastoma | 18 | 2023 | 262 | 1.930 |
Why?
| | Central Nervous System Cysts | 3 | 2020 | 12 | 1.830 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2022 | 900 | 1.670 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 90 | 1.480 |
Why?
| | Neurosurgical Procedures | 10 | 2021 | 164 | 1.450 |
Why?
| | Peripheral Nervous System Neoplasms | 6 | 2009 | 20 | 1.250 |
Why?
| | Glioma | 15 | 2020 | 306 | 1.090 |
Why?
| | Central Nervous System Neoplasms | 7 | 2017 | 128 | 1.090 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2016 | 128 | 0.970 |
Why?
| | Sphenoid Bone | 2 | 2016 | 16 | 0.970 |
Why?
| | Gliosarcoma | 5 | 2006 | 8 | 0.960 |
Why?
| | Cysts | 3 | 2020 | 93 | 0.870 |
Why?
| | Carmustine | 3 | 2017 | 47 | 0.820 |
Why?
| | Cancer Vaccines | 5 | 2018 | 139 | 0.800 |
Why?
| | Pituitary ACTH Hypersecretion | 2 | 2018 | 9 | 0.800 |
Why?
| | Neoplasms, Radiation-Induced | 4 | 2008 | 66 | 0.790 |
Why?
| | Hypopituitarism | 1 | 2020 | 15 | 0.750 |
Why?
| | Rhabdoid Tumor | 3 | 2010 | 80 | 0.740 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 189 | 0.680 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 114 | 0.680 |
Why?
| | Immunotherapy | 4 | 2006 | 493 | 0.660 |
Why?
| | Polyesters | 2 | 2017 | 65 | 0.650 |
Why?
| | Magnetic Resonance Imaging | 29 | 2022 | 3174 | 0.650 |
Why?
| | Decanoic Acids | 1 | 2017 | 7 | 0.640 |
Why?
| | Bleomycin | 1 | 2019 | 228 | 0.630 |
Why?
| | Adult | 70 | 2021 | 31512 | 0.630 |
Why?
| | Middle Aged | 71 | 2021 | 27617 | 0.620 |
Why?
| | Orbital Diseases | 1 | 2016 | 26 | 0.580 |
Why?
| | Aged | 52 | 2021 | 19657 | 0.560 |
Why?
| | Male | 84 | 2021 | 57801 | 0.510 |
Why?
| | Humans | 121 | 2023 | 118974 | 0.490 |
Why?
| | Female | 81 | 2021 | 61565 | 0.480 |
Why?
| | Brachial Plexus | 3 | 2007 | 29 | 0.450 |
Why?
| | Antineoplastic Agents | 5 | 2017 | 1974 | 0.450 |
Why?
| | Biomarkers, Tumor | 8 | 2017 | 1059 | 0.440 |
Why?
| | Immunotherapy, Adoptive | 5 | 1997 | 191 | 0.440 |
Why?
| | Retrospective Studies | 26 | 2022 | 12978 | 0.430 |
Why?
| | Dacarbazine | 7 | 2015 | 102 | 0.420 |
Why?
| | Cisplatin | 3 | 1998 | 271 | 0.410 |
Why?
| | Chemoradiotherapy | 4 | 2015 | 200 | 0.410 |
Why?
| | Skull Neoplasms | 4 | 2012 | 22 | 0.410 |
Why?
| | Craniopharyngioma | 3 | 2020 | 70 | 0.410 |
Why?
| | Cautery | 1 | 2010 | 3 | 0.390 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2013 | 69 | 0.380 |
Why?
| | Epithelioid Cells | 1 | 2010 | 8 | 0.370 |
Why?
| | Monosomy | 1 | 2010 | 10 | 0.370 |
Why?
| | Sella Turcica | 5 | 2018 | 12 | 0.370 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2010 | 39 | 0.370 |
Why?
| | Astrocytoma | 5 | 2014 | 113 | 0.360 |
Why?
| | Neurosurgery | 2 | 2021 | 29 | 0.360 |
Why?
| | Combined Modality Therapy | 11 | 2016 | 1166 | 0.360 |
Why?
| | Fibromatosis, Aggressive | 2 | 2007 | 19 | 0.360 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2010 | 103 | 0.350 |
Why?
| | Hemangioma | 1 | 2009 | 41 | 0.350 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2010 | 310 | 0.340 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 65 | 0.330 |
Why?
| | Membrane Proteins | 2 | 2017 | 1055 | 0.330 |
Why?
| | Spinal Nerve Roots | 2 | 2006 | 30 | 0.310 |
Why?
| | DNA Mutational Analysis | 3 | 2014 | 381 | 0.310 |
Why?
| | Fibromatosis, Abdominal | 1 | 2007 | 3 | 0.310 |
Why?
| | Immunohistochemistry | 13 | 2011 | 1691 | 0.300 |
Why?
| | Tumor Cells, Cultured | 7 | 2017 | 874 | 0.300 |
Why?
| | Young Adult | 14 | 2020 | 10793 | 0.300 |
Why?
| | Prolactinoma | 3 | 2019 | 11 | 0.290 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2006 | 10 | 0.280 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 33 | 0.280 |
Why?
| | Oligonucleotides, Antisense | 1 | 2006 | 100 | 0.280 |
Why?
| | Diagnosis, Differential | 8 | 2010 | 1384 | 0.280 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 2 | 2017 | 11 | 0.280 |
Why?
| | Gonadotrophs | 5 | 2015 | 21 | 0.280 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 64 | 0.280 |
Why?
| | Ethanol | 1 | 2010 | 575 | 0.270 |
Why?
| | Neoplasms | 5 | 2013 | 2179 | 0.270 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2017 | 1167 | 0.260 |
Why?
| | Rats, Inbred F344 | 7 | 2006 | 245 | 0.260 |
Why?
| | Treatment Outcome | 12 | 2020 | 9342 | 0.260 |
Why?
| | Postoperative Complications | 8 | 2018 | 2235 | 0.260 |
Why?
| | Adolescent | 20 | 2020 | 18480 | 0.260 |
Why?
| | Interleukin-2 | 6 | 1997 | 416 | 0.260 |
Why?
| | Oligonucleotide Array Sequence Analysis | 7 | 2015 | 770 | 0.250 |
Why?
| | DNA-Binding Proteins | 2 | 2010 | 1346 | 0.250 |
Why?
| | Hemangioblastoma | 1 | 2004 | 4 | 0.250 |
Why?
| | Neoplasms, Second Primary | 4 | 2012 | 93 | 0.240 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 152 | 0.240 |
Why?
| | Neurologic Examination | 3 | 2019 | 126 | 0.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 1390 | 0.230 |
Why?
| | Transcription Factors | 2 | 2010 | 1570 | 0.230 |
Why?
| | Cauda Equina | 2 | 2004 | 9 | 0.230 |
Why?
| | Inappropriate ADH Syndrome | 2 | 2018 | 8 | 0.230 |
Why?
| | Drug Implants | 3 | 2017 | 72 | 0.230 |
Why?
| | Postoperative Period | 3 | 2020 | 309 | 0.230 |
Why?
| | Motor Cortex | 1 | 2003 | 52 | 0.220 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2012 | 455 | 0.220 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2000 | 158 | 0.220 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 734 | 0.210 |
Why?
| | Pituitary Diseases | 3 | 2017 | 23 | 0.210 |
Why?
| | Prognosis | 10 | 2021 | 3443 | 0.210 |
Why?
| | Fistula | 1 | 2022 | 27 | 0.210 |
Why?
| | Intracranial Hypotension | 1 | 2022 | 16 | 0.210 |
Why?
| | Frontal Bone | 2 | 2015 | 13 | 0.210 |
Why?
| | Pinealoma | 1 | 2021 | 11 | 0.200 |
Why?
| | Pineal Gland | 1 | 2021 | 13 | 0.200 |
Why?
| | Aspergillus | 2 | 2013 | 18 | 0.200 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2014 | 202 | 0.200 |
Why?
| | Prospective Studies | 11 | 2023 | 6471 | 0.200 |
Why?
| | Follow-Up Studies | 8 | 2017 | 4596 | 0.200 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2016 | 56 | 0.200 |
Why?
| | Neuropathology | 1 | 2020 | 4 | 0.190 |
Why?
| | Telepathology | 1 | 2020 | 3 | 0.190 |
Why?
| | Ki-67 Antigen | 4 | 2011 | 108 | 0.190 |
Why?
| | Reactive Oxygen Species | 2 | 2000 | 576 | 0.190 |
Why?
| | Paraneoplastic Endocrine Syndromes | 1 | 2000 | 1 | 0.190 |
Why?
| | Esthesioneuroblastoma, Olfactory | 1 | 2000 | 1 | 0.190 |
Why?
| | Stereotaxic Techniques | 1 | 2020 | 28 | 0.190 |
Why?
| | Radiosurgery | 3 | 2010 | 318 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2021 | 76 | 0.190 |
Why?
| | Fluorescein | 1 | 2020 | 27 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 12 | 2022 | 2436 | 0.180 |
Why?
| | Salivary Glands | 1 | 2020 | 32 | 0.180 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2000 | 19 | 0.180 |
Why?
| | Nose Neoplasms | 1 | 2000 | 21 | 0.180 |
Why?
| | Survival Analysis | 7 | 2018 | 1267 | 0.180 |
Why?
| | Lung Neoplasms | 3 | 2013 | 2220 | 0.180 |
Why?
| | Aged, 80 and over | 12 | 2020 | 6561 | 0.180 |
Why?
| | Genes, Tumor Suppressor | 2 | 2017 | 77 | 0.170 |
Why?
| | Neoplasm Grading | 2 | 2017 | 258 | 0.170 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 4 | 0.170 |
Why?
| | Dendritic Cells | 2 | 2023 | 442 | 0.170 |
Why?
| | Polyethylenes | 1 | 2018 | 16 | 0.170 |
Why?
| | Hemangioma, Cavernous | 1 | 1998 | 16 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2015 | 360 | 0.170 |
Why?
| | Oligodendroglioma | 2 | 2014 | 15 | 0.170 |
Why?
| | Survival Rate | 6 | 2015 | 1720 | 0.170 |
Why?
| | Endocrine Glands | 1 | 1998 | 16 | 0.170 |
Why?
| | International Educational Exchange | 1 | 2018 | 11 | 0.170 |
Why?
| | ErbB Receptors | 4 | 2006 | 569 | 0.170 |
Why?
| | Sphenoid Sinus | 1 | 2018 | 9 | 0.170 |
Why?
| | Stroke | 2 | 2021 | 1047 | 0.160 |
Why?
| | Adenocarcinoma | 2 | 2004 | 812 | 0.160 |
Why?
| | Time Factors | 10 | 2011 | 6412 | 0.160 |
Why?
| | Antioxidants | 2 | 2000 | 564 | 0.160 |
Why?
| | Mutation | 3 | 2014 | 3457 | 0.160 |
Why?
| | Remission Induction | 1 | 2018 | 247 | 0.160 |
Why?
| | Hyponatremia | 1 | 2018 | 42 | 0.160 |
Why?
| | Cerebrovascular Disorders | 1 | 1998 | 86 | 0.160 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2017 | 23 | 0.160 |
Why?
| | Quinazolines | 2 | 2010 | 245 | 0.150 |
Why?
| | Thalamic Diseases | 1 | 2017 | 3 | 0.150 |
Why?
| | Rats | 8 | 2006 | 5392 | 0.150 |
Why?
| | Reoperation | 5 | 2020 | 557 | 0.150 |
Why?
| | Prostheses and Implants | 1 | 2018 | 141 | 0.150 |
Why?
| | Desmosomes | 1 | 2017 | 19 | 0.150 |
Why?
| | Xanthomatosis | 1 | 2017 | 11 | 0.150 |
Why?
| | Third Ventricle | 1 | 2017 | 14 | 0.150 |
Why?
| | Transcriptome | 2 | 2020 | 756 | 0.150 |
Why?
| | Exophthalmos | 1 | 2016 | 19 | 0.150 |
Why?
| | Students, Medical | 1 | 2021 | 311 | 0.150 |
Why?
| | Cell Proliferation | 5 | 2015 | 2275 | 0.140 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 968 | 0.140 |
Why?
| | Cytokines | 2 | 2021 | 1900 | 0.140 |
Why?
| | Brain Injuries | 1 | 2021 | 484 | 0.140 |
Why?
| | Antigens, Neoplasm | 2 | 2013 | 228 | 0.140 |
Why?
| | Progesterone | 1 | 2017 | 242 | 0.140 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 25 | 0.140 |
Why?
| | Neurothekeoma | 1 | 1995 | 4 | 0.140 |
Why?
| | Tibial Nerve | 1 | 1995 | 10 | 0.140 |
Why?
| | Occipital Lobe | 2 | 2006 | 23 | 0.140 |
Why?
| | Glycoproteins | 3 | 2012 | 319 | 0.130 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 69 | 0.130 |
Why?
| | Genes, p53 | 2 | 2011 | 64 | 0.130 |
Why?
| | Molecular Chaperones | 2 | 2013 | 174 | 0.130 |
Why?
| | Accidents, Aviation | 1 | 1994 | 4 | 0.130 |
Why?
| | Karyotyping | 3 | 2008 | 102 | 0.130 |
Why?
| | Olfactory Pathways | 1 | 2015 | 56 | 0.130 |
Why?
| | Orbit | 1 | 2015 | 59 | 0.130 |
Why?
| | Neoplasm Invasiveness | 6 | 2014 | 462 | 0.130 |
Why?
| | Biocompatible Materials | 1 | 2018 | 378 | 0.130 |
Why?
| | Cranial Irradiation | 1 | 1995 | 70 | 0.130 |
Why?
| | Acromegaly | 1 | 2014 | 15 | 0.130 |
Why?
| | Human Growth Hormone | 1 | 2014 | 37 | 0.120 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 6 | 0.120 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 42 | 0.120 |
Why?
| | Seizures | 1 | 2017 | 345 | 0.120 |
Why?
| | Intervertebral Disc Displacement | 2 | 1998 | 39 | 0.120 |
Why?
| | Cadherins | 1 | 2015 | 186 | 0.120 |
Why?
| | Ganglioglioma | 1 | 2014 | 35 | 0.120 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 21 | 0.120 |
Why?
| | Child | 9 | 2022 | 19129 | 0.120 |
Why?
| | Cerebral Hemorrhage | 2 | 1985 | 100 | 0.120 |
Why?
| | Immune Tolerance | 2 | 2008 | 334 | 0.120 |
Why?
| | Pituitary Gland, Posterior | 1 | 2013 | 3 | 0.120 |
Why?
| | Ganglioneuroma | 1 | 2013 | 2 | 0.120 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 1993 | 7 | 0.120 |
Why?
| | Gene Expression Profiling | 4 | 2020 | 1597 | 0.120 |
Why?
| | Aspergillosis | 1 | 2013 | 24 | 0.120 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 20 | 0.120 |
Why?
| | Telomerase | 3 | 2003 | 207 | 0.120 |
Why?
| | Joint Dislocations | 1 | 1993 | 59 | 0.110 |
Why?
| | Dog Diseases | 1 | 2013 | 44 | 0.110 |
Why?
| | Patient Readmission | 1 | 2018 | 634 | 0.110 |
Why?
| | Spinal Injuries | 1 | 1993 | 53 | 0.110 |
Why?
| | Neoplasm Transplantation | 3 | 2000 | 245 | 0.110 |
Why?
| | Soft Tissue Neoplasms | 1 | 1993 | 93 | 0.110 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2009 | 72 | 0.110 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1012 | 0.110 |
Why?
| | Muscles | 1 | 1993 | 333 | 0.110 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 38 | 0.110 |
Why?
| | Craniotomy | 3 | 2015 | 69 | 0.110 |
Why?
| | Curriculum | 1 | 2018 | 910 | 0.100 |
Why?
| | Spine | 1 | 1993 | 144 | 0.100 |
Why?
| | Research Design | 1 | 2017 | 969 | 0.100 |
Why?
| | Skull | 2 | 2007 | 127 | 0.100 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 79 | 0.100 |
Why?
| | Cell Division | 4 | 2012 | 776 | 0.100 |
Why?
| | Mitotic Index | 2 | 2011 | 27 | 0.100 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2010 | 7 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2674 | 0.100 |
Why?
| | Adenoma, Oxyphilic | 1 | 2010 | 5 | 0.090 |
Why?
| | SMARCB1 Protein | 1 | 2010 | 17 | 0.090 |
Why?
| | Tumor Burden | 4 | 2012 | 274 | 0.090 |
Why?
| | Claudins | 1 | 2010 | 24 | 0.090 |
Why?
| | Animals | 14 | 2013 | 33381 | 0.090 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 11 | 0.090 |
Why?
| | Lymphoma | 2 | 2008 | 180 | 0.090 |
Why?
| | Tanzania | 2 | 2020 | 45 | 0.090 |
Why?
| | Registries | 1 | 2017 | 1810 | 0.090 |
Why?
| | Proteome | 1 | 2013 | 353 | 0.090 |
Why?
| | Immunity, Cellular | 2 | 2003 | 270 | 0.090 |
Why?
| | Piperidines | 1 | 2010 | 171 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 289 | 0.090 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.090 |
Why?
| | Brain Abscess | 1 | 2008 | 11 | 0.080 |
Why?
| | Killer Cells, Lymphokine-Activated | 4 | 1993 | 9 | 0.080 |
Why?
| | Cytogenetics | 1 | 2008 | 10 | 0.080 |
Why?
| | Genetic Vectors | 2 | 2008 | 302 | 0.080 |
Why?
| | Internship and Residency | 1 | 2018 | 1001 | 0.080 |
Why?
| | Dogs | 2 | 2013 | 371 | 0.080 |
Why?
| | Arm Injuries | 1 | 1988 | 24 | 0.080 |
Why?
| | Prolactin | 3 | 2019 | 96 | 0.080 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2006 | 204 | 0.080 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 565 | 0.080 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 73 | 0.080 |
Why?
| | Radiotherapy Dosage | 3 | 2010 | 245 | 0.080 |
Why?
| | Interferon-beta | 1 | 2008 | 82 | 0.080 |
Why?
| | Superoxide Dismutase | 2 | 2000 | 339 | 0.080 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 736 | 0.080 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 8 | 0.080 |
Why?
| | Mesenchymoma | 1 | 2007 | 7 | 0.080 |
Why?
| | Wounds, Penetrating | 1 | 1988 | 77 | 0.080 |
Why?
| | Hematoma | 2 | 1985 | 51 | 0.080 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2007 | 18 | 0.080 |
Why?
| | Scalp | 1 | 2007 | 29 | 0.070 |
Why?
| | Child, Preschool | 5 | 2017 | 9491 | 0.070 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 384 | 0.070 |
Why?
| | Adenoviridae | 1 | 2008 | 191 | 0.070 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 29 | 0.070 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1223 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 1994 | 772 | 0.070 |
Why?
| | Cell Survival | 4 | 2015 | 1047 | 0.070 |
Why?
| | Dexamethasone | 4 | 2012 | 320 | 0.070 |
Why?
| | Blood Vessels | 1 | 1988 | 187 | 0.070 |
Why?
| | Enophthalmos | 1 | 2006 | 1 | 0.070 |
Why?
| | Blepharoptosis | 1 | 2006 | 6 | 0.070 |
Why?
| | Radiography | 3 | 2013 | 861 | 0.070 |
Why?
| | Base Pair Mismatch | 1 | 2006 | 15 | 0.070 |
Why?
| | Hemangioma, Capillary | 1 | 2006 | 13 | 0.070 |
Why?
| | Vaccination | 2 | 2023 | 1222 | 0.070 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 138 | 0.070 |
Why?
| | Epidermal Cyst | 1 | 2006 | 12 | 0.070 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 64 | 0.070 |
Why?
| | Parietal Lobe | 1 | 2006 | 42 | 0.070 |
Why?
| | Teratoma | 1 | 2007 | 92 | 0.070 |
Why?
| | Immunoprecipitation | 1 | 2006 | 161 | 0.070 |
Why?
| | Lymphoma, Follicular | 1 | 2006 | 29 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 404 | 0.070 |
Why?
| | Genetic Therapy | 1 | 2008 | 267 | 0.070 |
Why?
| | Neoplasm, Residual | 2 | 2020 | 103 | 0.070 |
Why?
| | Chest Pain | 1 | 2006 | 84 | 0.070 |
Why?
| | Brain Edema | 2 | 2004 | 61 | 0.070 |
Why?
| | Karnofsky Performance Status | 3 | 2013 | 36 | 0.070 |
Why?
| | Bone Diseases | 1 | 2006 | 59 | 0.070 |
Why?
| | Benzamides | 1 | 2006 | 176 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2006 | 3730 | 0.070 |
Why?
| | Databases, Factual | 1 | 2010 | 1231 | 0.070 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 185 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2015 | 2851 | 0.070 |
Why?
| | Ultrasonics | 2 | 2002 | 53 | 0.070 |
Why?
| | Exons | 1 | 2006 | 307 | 0.070 |
Why?
| | Lymphoma, B-Cell | 1 | 2006 | 85 | 0.070 |
Why?
| | Wounds, Nonpenetrating | 1 | 1988 | 285 | 0.060 |
Why?
| | United States | 3 | 2017 | 12555 | 0.060 |
Why?
| | Medulloblastoma | 1 | 2007 | 177 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1868 | 0.060 |
Why?
| | Myelography | 2 | 2022 | 19 | 0.060 |
Why?
| | Cushing Syndrome | 1 | 2004 | 10 | 0.060 |
Why?
| | Calcitonin | 1 | 2004 | 29 | 0.060 |
Why?
| | Bevacizumab | 2 | 2015 | 124 | 0.060 |
Why?
| | Subarachnoid Space | 1 | 2004 | 8 | 0.060 |
Why?
| | S100 Proteins | 2 | 1995 | 35 | 0.060 |
Why?
| | von Hippel-Lindau Disease | 1 | 2004 | 12 | 0.060 |
Why?
| | Brain | 6 | 2017 | 2490 | 0.060 |
Why?
| | Quality of Life | 2 | 2013 | 2366 | 0.060 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 17 | 0.060 |
Why?
| | Piperazines | 1 | 2006 | 316 | 0.060 |
Why?
| | Craniocerebral Trauma | 1 | 1985 | 146 | 0.060 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 18 | 0.060 |
Why?
| | Radiotherapy | 1 | 2004 | 187 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 982 | 0.060 |
Why?
| | Lymphocyte Activation | 3 | 1993 | 1067 | 0.060 |
Why?
| | Pyrimidines | 1 | 2006 | 382 | 0.060 |
Why?
| | Disease Progression | 2 | 2021 | 2490 | 0.060 |
Why?
| | Dura Mater | 2 | 2000 | 29 | 0.060 |
Why?
| | Age Factors | 4 | 2014 | 2995 | 0.060 |
Why?
| | Incidence | 3 | 2003 | 2424 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 551 | 0.050 |
Why?
| | Image Enhancement | 1 | 2004 | 181 | 0.050 |
Why?
| | Polymers | 2 | 1997 | 482 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2004 | 273 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2003 | 401 | 0.050 |
Why?
| | Transferases | 1 | 2022 | 27 | 0.050 |
Why?
| | Cell Movement | 1 | 2006 | 896 | 0.050 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2022 | 28 | 0.050 |
Why?
| | Drug Resistance, Multiple | 1 | 2001 | 19 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3171 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 2003 | 188 | 0.050 |
Why?
| | Hyperthermia, Induced | 1 | 2002 | 67 | 0.050 |
Why?
| | DNA, Neoplasm | 3 | 2005 | 154 | 0.050 |
Why?
| | Thyrotropin | 5 | 1999 | 105 | 0.050 |
Why?
| | Spinal Cord | 1 | 2004 | 367 | 0.050 |
Why?
| | Public Opinion | 1 | 2021 | 59 | 0.050 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 681 | 0.050 |
Why?
| | Neuroimmunomodulation | 1 | 2000 | 72 | 0.050 |
Why?
| | Gene Amplification | 2 | 2015 | 97 | 0.050 |
Why?
| | Surgical Wound Infection | 1 | 2003 | 251 | 0.050 |
Why?
| | Ethmoid Sinus | 1 | 2000 | 8 | 0.050 |
Why?
| | Frontal Sinus | 1 | 2000 | 4 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2021 | 147 | 0.050 |
Why?
| | Visual Fields | 1 | 2020 | 78 | 0.050 |
Why?
| | Arginine Vasopressin | 1 | 2000 | 47 | 0.050 |
Why?
| | Free Radicals | 1 | 2000 | 104 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 1999 | 16 | 0.050 |
Why?
| | Depressive Disorder, Major | 1 | 2003 | 303 | 0.050 |
Why?
| | Dopamine Agonists | 1 | 2019 | 30 | 0.050 |
Why?
| | Recurrence | 1 | 2023 | 975 | 0.040 |
Why?
| | Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2007 | 762 | 0.040 |
Why?
| | Infant | 2 | 2008 | 8293 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 2005 | 15 | 0.040 |
Why?
| | Hot Temperature | 1 | 2001 | 334 | 0.040 |
Why?
| | Cerebral Cortex | 2 | 1998 | 416 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 306 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 1998 | 33 | 0.040 |
Why?
| | Up-Regulation | 2 | 2015 | 872 | 0.040 |
Why?
| | Visual Acuity | 1 | 2020 | 272 | 0.040 |
Why?
| | Cerebral Veins | 1 | 1998 | 16 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 5 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2003 | 671 | 0.040 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 10 | 0.040 |
Why?
| | Capacity Building | 1 | 2018 | 51 | 0.040 |
Why?
| | Apoptosis | 2 | 2015 | 2484 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 119 | 0.040 |
Why?
| | Catheters, Indwelling | 1 | 1998 | 81 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1079 | 0.040 |
Why?
| | Leiomyosarcoma | 1 | 1998 | 23 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2018 | 69 | 0.040 |
Why?
| | Preoperative Care | 2 | 2003 | 332 | 0.040 |
Why?
| | Meningomyelocele | 1 | 1998 | 51 | 0.040 |
Why?
| | Drug Synergism | 1 | 1998 | 339 | 0.040 |
Why?
| | Leiomyoma | 1 | 1998 | 45 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2000 | 317 | 0.040 |
Why?
| | Hypophysitis | 1 | 2017 | 2 | 0.040 |
Why?
| | DNA Methylation | 1 | 2022 | 503 | 0.040 |
Why?
| | Hydrocephalus | 2 | 2017 | 81 | 0.040 |
Why?
| | Cell Line | 3 | 2012 | 2707 | 0.040 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 1997 | 13 | 0.040 |
Why?
| | Brain Diseases | 2 | 1998 | 140 | 0.040 |
Why?
| | Neuroendoscopy | 1 | 2017 | 14 | 0.040 |
Why?
| | Ventriculostomy | 1 | 2017 | 19 | 0.040 |
Why?
| | Premenopause | 1 | 2017 | 108 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2000 | 736 | 0.040 |
Why?
| | Gonadotropins | 2 | 1999 | 37 | 0.040 |
Why?
| | Microarray Analysis | 1 | 2017 | 124 | 0.040 |
Why?
| | Postoperative Care | 1 | 1998 | 237 | 0.040 |
Why?
| | Injections, Intraperitoneal | 1 | 1996 | 108 | 0.040 |
Why?
| | Developing Countries | 1 | 2018 | 255 | 0.040 |
Why?
| | RNA, Messenger | 5 | 2011 | 2657 | 0.040 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 195 | 0.040 |
Why?
| | Granuloma | 1 | 2017 | 87 | 0.040 |
Why?
| | Immunophenotyping | 1 | 1997 | 278 | 0.040 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 93 | 0.040 |
Why?
| | Biodegradation, Environmental | 1 | 1996 | 81 | 0.040 |
Why?
| | Drainage | 1 | 2017 | 157 | 0.040 |
Why?
| | Delayed-Action Preparations | 1 | 1997 | 161 | 0.040 |
Why?
| | Intraoperative Complications | 1 | 2017 | 132 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2005 | 1200 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 272 | 0.030 |
Why?
| | Hyperostosis | 1 | 1995 | 6 | 0.030 |
Why?
| | Computational Biology | 1 | 2020 | 588 | 0.030 |
Why?
| | Signal Transduction | 3 | 2015 | 4709 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2015 | 529 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2018 | 252 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 907 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 294 | 0.030 |
Why?
| | Olfactory Nerve | 1 | 2015 | 9 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 184 | 0.030 |
Why?
| | Lactic Acid | 1 | 1997 | 282 | 0.030 |
Why?
| | Cysticercosis | 1 | 1995 | 4 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 35 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4196 | 0.030 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 1995 | 24 | 0.030 |
Why?
| | Nasal Cavity | 1 | 2015 | 47 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 55 | 0.030 |
Why?
| | Audiometry | 1 | 1995 | 33 | 0.030 |
Why?
| | Seat Belts | 1 | 1994 | 17 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1388 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1995 | 45 | 0.030 |
Why?
| | Cerebral Arteries | 1 | 2015 | 56 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2006 | 4077 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 40 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 100 | 0.030 |
Why?
| | Aircraft | 1 | 1994 | 28 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 1995 | 116 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 43 | 0.030 |
Why?
| | Personality Disorders | 1 | 2015 | 68 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1032 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 1993 | 1308 | 0.030 |
Why?
| | Neuroimaging | 1 | 2016 | 256 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1998 | 709 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 220 | 0.030 |
Why?
| | Cohort Studies | 2 | 2017 | 5116 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 167 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2015 | 158 | 0.030 |
Why?
| | Computer Simulation | 1 | 1998 | 922 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 285 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 205 | 0.030 |
Why?
| | Paresis | 2 | 2007 | 31 | 0.030 |
Why?
| | Nervous System | 1 | 1993 | 66 | 0.030 |
Why?
| | Mice | 4 | 2012 | 15520 | 0.030 |
Why?
| | Hypothyroidism | 2 | 1992 | 68 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 246 | 0.030 |
Why?
| | Antibodies, Monoclonal | 4 | 2008 | 1284 | 0.030 |
Why?
| | Neuroblastoma | 1 | 1993 | 135 | 0.030 |
Why?
| | Safety | 1 | 1994 | 304 | 0.030 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1992 | 34 | 0.030 |
Why?
| | Models, Biological | 1 | 2000 | 1715 | 0.030 |
Why?
| | Chronic Disease | 1 | 2018 | 1636 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 420 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 1993 | 222 | 0.030 |
Why?
| | Vimentin | 1 | 1992 | 62 | 0.030 |
Why?
| | Fatal Outcome | 2 | 2007 | 287 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2874 | 0.030 |
Why?
| | G2 Phase | 1 | 2012 | 33 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1993 | 189 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 823 | 0.030 |
Why?
| | Lymphocytosis | 1 | 1992 | 9 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 1945 | 0.030 |
Why?
| | Lymphocytes | 1 | 1993 | 347 | 0.030 |
Why?
| | CpG Islands | 1 | 2012 | 119 | 0.030 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 113 | 0.030 |
Why?
| | Cavernous Sinus | 1 | 2011 | 16 | 0.030 |
Why?
| | Stress, Physiological | 1 | 2015 | 415 | 0.030 |
Why?
| | Skull Base | 1 | 2011 | 44 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2014 | 1293 | 0.030 |
Why?
| | Cytoplasm | 1 | 2012 | 269 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 604 | 0.020 |
Why?
| | Intraoperative Care | 2 | 2003 | 39 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1991 | 49 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 143 | 0.020 |
Why?
| | Algorithms | 1 | 1998 | 1541 | 0.020 |
Why?
| | Spleen | 1 | 1993 | 510 | 0.020 |
Why?
| | Carcinoma | 1 | 2012 | 204 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 395 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 71 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 99 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 142 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 100 | 0.020 |
Why?
| | Vision Disorders | 2 | 2007 | 135 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2010 | 140 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 359 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 130 | 0.020 |
Why?
| | Hypogonadism | 1 | 1990 | 77 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 230 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 3 | 1999 | 216 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 1781 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 18 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 28 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 357 | 0.020 |
Why?
| | Kinetics | 1 | 1992 | 1624 | 0.020 |
Why?
| | Ultrasonography | 2 | 1984 | 716 | 0.020 |
Why?
| | Axillary Artery | 1 | 1988 | 13 | 0.020 |
Why?
| | Infant, Newborn | 3 | 1997 | 5255 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 92 | 0.020 |
Why?
| | Subclavian Artery | 1 | 1988 | 31 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 82 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1992 | 398 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 465 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 756 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3057 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 38 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 827 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 155 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1158 | 0.020 |
Why?
| | Methotrexate | 1 | 2008 | 227 | 0.020 |
Why?
| | Proteomics | 1 | 2013 | 876 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 533 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1125 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1992 | 448 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 369 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 413 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 200 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1989 | 1094 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 545 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 137 | 0.020 |
Why?
| | Tretinoin | 1 | 2006 | 116 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 394 | 0.020 |
Why?
| | Cognition | 1 | 2013 | 1024 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 306 | 0.020 |
Why?
| | Coma | 1 | 1985 | 32 | 0.020 |
Why?
| | Action Potentials | 1 | 1988 | 420 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 336 | 0.020 |
Why?
| | Intracranial Pressure | 1 | 1985 | 53 | 0.020 |
Why?
| | Athletic Injuries | 1 | 1991 | 495 | 0.020 |
Why?
| | Brain Concussion | 1 | 1991 | 470 | 0.020 |
Why?
| | Blood-Brain Barrier | 1 | 1985 | 108 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 940 | 0.020 |
Why?
| | Citrates | 1 | 1984 | 48 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2008 | 688 | 0.010 |
Why?
| | Antigens, CD | 1 | 2006 | 460 | 0.010 |
Why?
| | Blood | 1 | 1984 | 100 | 0.010 |
Why?
| | Sound | 1 | 1984 | 68 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2003 | 44 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2275 | 0.010 |
Why?
| | Injections | 1 | 1984 | 167 | 0.010 |
Why?
| | Trauma Centers | 1 | 1985 | 388 | 0.010 |
Why?
| | Heparin | 1 | 1984 | 230 | 0.010 |
Why?
| | Rhodamine 123 | 1 | 2001 | 3 | 0.010 |
Why?
| | Cyclosporins | 1 | 2001 | 60 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 2001 | 73 | 0.010 |
Why?
| | Pulsatile Flow | 2 | 1991 | 54 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 155 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 1985 | 545 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1489 | 0.010 |
Why?
| | Lung | 1 | 2013 | 3664 | 0.010 |
Why?
| | Doxorubicin | 1 | 2001 | 302 | 0.010 |
Why?
| | Luteinizing Hormone | 2 | 1991 | 173 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1999 | 5 | 0.010 |
Why?
| | Steroidogenic Factor 1 | 1 | 1999 | 6 | 0.010 |
Why?
| | Transcription Factor Pit-1 | 1 | 1999 | 23 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 978 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2071 | 0.010 |
Why?
| | Brown-Sequard Syndrome | 1 | 1998 | 5 | 0.010 |
Why?
| | Syringomyelia | 1 | 1998 | 11 | 0.010 |
Why?
| | Pyramidal Tracts | 1 | 1998 | 20 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2871 | 0.010 |
Why?
| | Sensation Disorders | 1 | 1998 | 33 | 0.010 |
Why?
| | Iatrogenic Disease | 1 | 1998 | 49 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 1998 | 72 | 0.010 |
Why?
| | Therapy, Computer-Assisted | 1 | 1998 | 60 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 195 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 41 | 0.010 |
Why?
| | Photography | 1 | 1998 | 93 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 75 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 1998 | 126 | 0.010 |
Why?
| | Spinal Fractures | 1 | 1998 | 77 | 0.010 |
Why?
| | Cervical Vertebrae | 1 | 1998 | 115 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2006 | 4908 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 332 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 142 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 224 | 0.010 |
Why?
| | Lumbar Vertebrae | 1 | 1998 | 215 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1999 | 468 | 0.010 |
Why?
| | Spinal Cord Injuries | 1 | 1998 | 184 | 0.010 |
Why?
| | Praziquantel | 1 | 1995 | 5 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1995 | 33 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 572 | 0.010 |
Why?
| | Carotid Stenosis | 1 | 1995 | 75 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1795 | 0.010 |
Why?
| | Optic Chiasm | 1 | 1992 | 18 | 0.010 |
Why?
| | Unconsciousness | 1 | 1991 | 24 | 0.010 |
Why?
| | Nerve Compression Syndromes | 1 | 1992 | 30 | 0.010 |
Why?
| | Amnesia | 1 | 1991 | 46 | 0.010 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1992 | 51 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 185 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 4708 | 0.010 |
Why?
| | Headache | 1 | 1992 | 128 | 0.010 |
Why?
| | Football | 1 | 1991 | 89 | 0.010 |
Why?
| | Immunochemistry | 1 | 1989 | 13 | 0.010 |
Why?
| | Autoradiography | 1 | 1989 | 72 | 0.010 |
Why?
| | Hyperthyroidism | 1 | 1989 | 26 | 0.010 |
Why?
| | Histocytochemistry | 1 | 1989 | 82 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 1991 | 401 | 0.010 |
Why?
| | Neutrophils | 1 | 1989 | 1233 | 0.000 |
Why?
| | Transcription, Genetic | 1 | 1989 | 1323 | 0.000 |
Why?
| | Intraoperative Period | 1 | 1982 | 55 | 0.000 |
Why?
| | Arteriovenous Malformations | 1 | 1982 | 24 | 0.000 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 1982 | 31 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1989 | 1774 | 0.000 |
Why?
| | Phenotype | 1 | 1989 | 3003 | 0.000 |
Why?
| | Pregnancy | 1 | 1992 | 5691 | 0.000 |
Why?
| | Gene Expression Regulation | 1 | 1989 | 2445 | 0.000 |
Why?
|
|
Lillehei's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|